Companies / iECURE
iECURE
Company
The company is advancing innovative genetic therapies designed to address the underlying cause of neurometabolic disorders.
iECURE has 2 investors on file, among them Double Point Ventures and Versant Ventures. Its site was last checked 13 Nov 2026: site answers.
Investors
2 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital | |
| Portfolio page | Venture capital |
More from Double Point Ventures
13 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (100%).
See Double Point Ventures' full profile · Who invests alongside it
More from Versant Ventures
59 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (90%), AI & Machine Learning (3%), Robotics & Hardware (2%).
See Versant Ventures' full profile · Who invests alongside it
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get iECURE and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Double Point Ventures adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/iecure.com/investors
# also
GET /v1/companies/iecure.com
GET /v1/companies/iecure.com/news